Madrigal Pharmaceuticals (MDGL) Free Cash Flow (2010 - 2026)
Madrigal Pharmaceuticals (MDGL) reported Free Cash Flow of -$171.3 million for Q1 2026, down 92.69% year-over-year from -$2.3 billion in Q1 2025, and down 28.59% quarter-over-quarter from -$133.2 million in Q4 2025.
Madrigal Pharmaceuticals (MDGL) Free Cash Flow (2010 - 2026) Analysis & Trends
Madrigal Pharmaceuticals (MDGL) has 17 years of Free Cash Flow data on file, last reported at -$171.3 million in Q1 2026.
- Free Cash Flow for Q1 2026 came in at -$171.3 million, down 92.69% year-over-year; the trailing twelve-month figure through Mar 2026 was -$272.4 million (up 31.28% YoY), and the FY2025 annual result was -$190.0 million, up 58.42% from the prior year.
- Free Cash Flow slipped to -$171.3 million in Q1 2026 per MDGL's latest filing, from -$133.2 million in the prior quarter.
- Over five years, Free Cash Flow peaked at $79.1 million in Q3 2025 and troughed at -$171.3 million in Q1 2026.
- A 5-year average of -$80.5 million and a median of -$81.0 million in 2023 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2025 and 2026: Free Cash Flow surged 218.99% in 2025, then sank 92.69% in 2026.
- A 5-year view of Free Cash Flow shows it stood at -$58.5 million in 2022, then plunged by 38.3% to -$81.0 million in 2023, then plunged by 30.85% to -$105.9 million in 2024, then retreated by 25.72% to -$133.2 million in 2025, then fell by 28.59% to -$171.3 million in 2026.
- Business Quant data shows MDGL's Free Cash Flow at -$171.3 million in Q1 2026, -$133.2 million in Q4 2025, and $79.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 63,220.27 |
| 10 | Madrigal Pharmaceuticals | 14.67 Bn | 14.44 Bn | - | -171.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -171.28 Mn |
| Mar 31, 2026 | -171.28 Mn |
| Dec 31, 2025 | -133.20 Mn |
| Dec 31, 2025 | -133.20 Mn |
| Sep 30, 2025 | 79.12 Mn |
| Sep 30, 2025 | 79.12 Mn |
| Jun 30, 2025 | -47.05 Mn |
| Jun 30, 2025 | -47.05 Mn |
| Mar 31, 2025 | -88.89 Mn |
| Mar 31, 2025 | -88.89 Mn |
| Dec 31, 2024 | -105.95 Mn |
| Dec 31, 2024 | -105.95 Mn |
| Sep 30, 2024 | -66.50 Mn |
| Sep 30, 2024 | -66.50 Mn |
| Jun 30, 2024 | -135.08 Mn |
| Jun 30, 2024 | -135.08 Mn |
| Mar 31, 2024 | -149.51 Mn |
| Mar 31, 2024 | -149.51 Mn |
| Dec 31, 2023 | -80.97 Mn |
| Dec 31, 2023 | -80.97 Mn |